Hennion & Walsh Asset Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Hennion & Walsh Asset Management’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.13M	Sell	112,893 -988	-0.9%	-$8.93K	0.03%	529
2026 Q1	$1.08M	Buy	113,881 +1,342	+1%	+$10.4K	0.04%	494
2025 Q4	$878K	Buy	112,539 +26,794	+31%	+$194K	0.03%	556
2025 Q3	$651K	Buy	85,745 +35,290	+70%	+$294K	0.02%	635
2025 Q2	$452K	Buy	+50,455	New	+$470K	0.02%	701

Other funds holding BCRX

NFT

Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return

WCM

Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return

Doliver Advisors Houston, Texas $442M AUM 34.09% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Counterweight Ventures Wilmington, North Carolina $201M AUM 35.56% 1-Year Est. Return

Grimes & Company Westborough, Massachusetts $4.62B AUM 29.71% 1-Year Est. Return

EWM

Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return

CUAMC

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

Hennion & Walsh Asset Management's BCRX Position: Q2 2026 in Review

Hennion & Walsh Asset Management reduced its BioCryst Pharmaceuticals (BCRX) stake by 0.87% in Q2 2026, selling an estimated $8.93K and leaving 112,893 shares worth $1.13M. The position accounts for 0.03% of the portfolio, ranked #529.

Hennion & Walsh Asset Management first reported a position in BCRX in Q2 2025 and has held it in 5 quarters since. 40 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

Hennion & Walsh Asset Management held 112,893 shares of BioCryst Pharmaceuticals worth $1.13M as of Q2 2026.
Hennion & Walsh Asset Management sold 988 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $8.93K.
BioCryst Pharmaceuticals made up 0.03% of Hennion & Walsh Asset Management's portfolio in Q2 2026, its #529 holding.
Hennion & Walsh Asset Management first reported a position in BioCryst Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
40 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Hennion & Walsh Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.